JESSICA WOOD: Open Payments
NPI 1134903347 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$758 in 23 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $758
Food & beverage: $758
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $267 |
| Amgen Inc. | 2 | $232 |
| Novo Nordisk Inc | 2 | $57 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| Alexion Pharmaceuticals, Inc. | 1 | $28 |
| Calliditas Therapeutics US Inc. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| NxStage Medical, Inc. | 1 | $19 |
Products named: TAVNEOS, Vanrafia, Fabhalta, Ozempic, Kerendia, JARDIANCE, LOKELMA, ULTOMIRIS.
Industry payments across CO — which companies pay providers there.
